Literature DB >> 35255387

Glycosylation as a key parameter in the design of nucleic acid vaccines.

Ahmet Ozdilek1, Fikri Y Avci2.   

Abstract

Vaccine-induced immunity is expected to target the native antigens expressed by the pathogens. Therefore, it is highly important to generate vaccine antigens that are immunologically indistinguishable from the native antigens. Nucleic acid vaccines, comprised of DNA, mRNA, or recombinant viral vector vaccines, introduce the genetic material encoding the antigenic protein for the host to express. Because these proteins will undergo host posttranslational modifications, host glycosylation can potentially alter the structure and immunological efficacy of the antigen. In this review, we discuss the potential impact of host protein glycosylation on the immune responses generated by nucleic acid vaccines against bacterial and viral pathogens.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35255387      PMCID: PMC8957583          DOI: 10.1016/j.sbi.2022.102348

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN: 0959-440X            Impact factor:   6.809


  55 in total

1.  A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Authors:  M Tameris; D A Hokey; V Nduba; J Sacarlal; F Laher; G Kiringa; K Gondo; E M Lazarus; G E Gray; S Nachman; H Mahomed; K Downing; B Abel; T J Scriba; J B McClain; M G Pau; J Hendriks; V Dheenadhayalan; S Ishmukhamedov; A K K Luabeya; H Geldenhuys; B Shepherd; G Blatner; V Cardenas; R Walker; W A Hanekom; J Sadoff; M Douoguih; L Barker; M Hatherill
Journal:  Vaccine       Date:  2015-04-28       Impact factor: 3.641

2.  Since there are PAMPs and DAMPs, there must be SAMPs? Glycan “self-associated molecular patterns” dampen innate immunity, but pathogens can mimic them.

Authors:  Ajit Varki
Journal:  Glycobiology       Date:  2011-09       Impact factor: 4.313

3.  Interferon-α alters host glycosylation machinery during treated HIV infection.

Authors:  Leila B Giron; Florent Colomb; Emmanouil Papasavvas; Livio Azzoni; Xiangfan Yin; Matthew Fair; Alitzel Anzurez; Mohammad Damra; Karam Mounzer; Jay R Kostman; Pablo Tebas; Una O'Doherty; Hiroaki Tateno; Qin Liu; Michael R Betts; Luis J Montaner; Mohamed Abdel-Mohsen
Journal:  EBioMedicine       Date:  2020-08-19       Impact factor: 8.143

4.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

Authors:  Jason S McLellan; Marie Pancera; Chris Carrico; Jason Gorman; Jean-Philippe Julien; Reza Khayat; Robert Louder; Robert Pejchal; Mallika Sastry; Kaifan Dai; Sijy O'Dell; Nikita Patel; Syed Shahzad-ul-Hussan; Yongping Yang; Baoshan Zhang; Tongqing Zhou; Jiang Zhu; Jeffrey C Boyington; Gwo-Yu Chuang; Devan Diwanji; Ivelin Georgiev; Young Do Kwon; Doyung Lee; Mark K Louder; Stephanie Moquin; Stephen D Schmidt; Zhi-Yong Yang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Dennis R Burton; Wayne C Koff; Laura M Walker; Sanjay Phogat; Richard Wyatt; Jared Orwenyo; Lai-Xi Wang; James Arthos; Carole A Bewley; John R Mascola; Gary J Nabel; William R Schief; Andrew B Ward; Ian A Wilson; Peter D Kwong
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

Review 5.  Engineering DNA vaccines against infectious diseases.

Authors:  Jihui Lee; Shreedevi Arun Kumar; Yong Yu Jhan; Corey J Bishop
Journal:  Acta Biomater       Date:  2018-08-31       Impact factor: 8.947

6.  A cross-neutralizing antibody between HIV-1 and influenza virus.

Authors:  Chang-Chun D Lee; Yasunori Watanabe; Nicholas C Wu; Julianna Han; Sonu Kumar; Tossapol Pholcharee; Gemma E Seabright; Joel D Allen; Chih-Wei Lin; Ji-Rong Yang; Ming-Tsan Liu; Chung-Yi Wu; Andrew B Ward; Max Crispin; Ian A Wilson
Journal:  PLoS Pathog       Date:  2021-03-22       Impact factor: 6.823

Review 7.  Self-amplifying RNA vaccines for infectious diseases.

Authors:  Kristie Bloom; Fiona van den Berg; Patrick Arbuthnot
Journal:  Gene Ther       Date:  2020-10-22       Impact factor: 5.250

8.  Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.

Authors:  Peng Zhao; Jeremy L Praissman; Oliver C Grant; Yongfei Cai; Tianshu Xiao; Katelyn E Rosenbalm; Kazuhiro Aoki; Benjamin P Kellman; Robert Bridger; Dan H Barouch; Melinda A Brindley; Nathan E Lewis; Michael Tiemeyer; Bing Chen; Robert J Woods; Lance Wells
Journal:  Cell Host Microbe       Date:  2020-08-24       Impact factor: 21.023

Review 9.  HIV and Messenger RNA (mRNA) Vaccine.

Authors:  Khizer Khalid; Jaskamal Padda; Anwar Khedr; Dina Ismail; Ujala Zubair; Ola A Al-Ewaidat; Sandeep Padda; Ayden Charlene Cooper; Gutteridge Jean-Charles
Journal:  Cureus       Date:  2021-07-05
View more
  3 in total

1.  Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry.

Authors:  Edwin E Escobar; Shuaishuai Wang; Rupanjan Goswami; Michael B Lanzillotti; Lei Li; Jason S McLellan; Jennifer S Brodbelt
Journal:  Anal Chem       Date:  2022-04-07       Impact factor: 8.008

Review 2.  Transient Expression of Glycosylated SARS-CoV-2 Antigens in Nicotiana benthamiana.

Authors:  Valentina Ruocco; Richard Strasser
Journal:  Plants (Basel)       Date:  2022-04-18

3.  In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine.

Authors:  Seyedeh Zeinab Masoomi Nomandan; Maryam Azimzadeh Irani; Seyed Masoud Hosseini
Journal:  Front Mol Biosci       Date:  2022-09-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.